Morgan Stanley Cuts Holding in Spark Therapeutics Inc (ONCE)

Morgan Stanley Cuts Holding in Spark Therapeutics Inc (ONCE)

Morgan Stanley decreased its holdings in Spark Therapeutics Inc (NASDAQ:ONCE) by 65.8% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 157,835 shares of the biotechnology company’s stock after selling 304,286 shares during the quarter. Morgan Stanley’s holdings in Spark Therapeutics were worth $8,610,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Harel Insurance Investments & Financial Services Ltd. acquired a new stake in Spark Therapeutics in the third quarter valued at approximately $122,000. Bank of Montreal Can grew its position in Spark Therapeutics by 1,045.4% in the third quarter. Bank of Montreal Can now owns 3,253 shares of the biotechnology company’s stock valued at $177,000 after acquiring an additional 2,969 shares in the last quarter. Shell Asset Management Co. acquired a new stake in Spark Therapeutics in the third quarter valued at approximately $208,000. Smith Asset Management Group LP grew its position in Spark Therapeutics by 39.6% in the third quarter. Smith Asset Management Group LP now owns 3,950 shares of the biotechnology company’s stock valued at $215,000 after acquiring an additional 1,120 shares in the last quarter. Finally, Tower Research Capital LLC TRC grew its position in Spark Therapeutics by 37,036.4% in the third quarter. Tower Research Capital LLC TRC now owns 4,085 shares of the biotechnology company’s stock valued at $223,000 after acquiring an additional 4,074 shares in the last quarter.

Several brokerages have issued reports on ONCE. Credit Suisse Group reaffirmed a “hold” rating and issued a $44.00 price objective on shares of Spark Therapeutics in a research report on Friday. ValuEngine raised shares of Spark Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, November 1st. Mizuho decreased their price target on shares of Spark Therapeutics to $62.00 and set a “buy” rating for the company in a research report on Wednesday, November 7th. Zacks Investment Research downgraded shares of Spark Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, November 8th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $80.00 price target (down previously from $103.00) on shares of Spark Therapeutics in a research report on Thursday, January 10th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and twelve have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $65.20.

ONCE stock opened at $48.05 on Tuesday. Spark Therapeutics Inc has a twelve month low of $34.53 and a twelve month high of $96.59. The company has a debt-to-equity ratio of 0.09, a current ratio of 10.71 and a quick ratio of 10.36. The company has a market cap of $1.81 billion, a PE ratio of -6.30 and a beta of 2.06.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia.

See Also: Why is the Consumer Price Index (CPI) important?

Want to see what other hedge funds are holding ONCE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Spark Therapeutics Inc (NASDAQ:ONCE).

Related posts

Leave a Comment